4th Quarter - Report

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION

Firm
Client
Income
—
Expenses
$610,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Transatlantic Trade & Investment Partnership (TTIP)

LobbyistCovered position, as disclosed
PAUL ROMNESS —
ALANNA PORTER TEMME —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Copyright/Patent/Trademark CPT

Patent Settlements; Patent Trolls (H.R. 3390)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
JONATHAN REA MCPHERSON —
PAUL ROMNESS —
ALANNA PORTER TEMME —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3390 (113th)

Health Issues HCR

Healthcare Exchanges; Protected Classes

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
JONATHAN REA MCPHERSON —
ALANNA PORTER TEMME —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Average Sales Price; Reimbursement

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Animals ANI

Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
ALANNA PORTER TEMME —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: S. 622 (113th), H.R. 3204 (113th), H.R. 6432 (113th)

Budget/Appropriations BUD

Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain (H.R. 2775)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
JONATHAN REA MCPHERSON —
ALANNA PORTER TEMME —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2775 (113th)

Consumer Issues/Safety/Products CSP

Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
JONATHAN REA MCPHERSON —
PAUL ROMNESS —
ALANNA PORTER TEMME —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.